Bu sayfanın çevirisi deneyseldir ve geliştirilme aşamasındadır. imlerinizi bekliyoruz!

Astellas Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Astellas Pharma şirketinin toplam hissedar öz sermayesi ¥1,676.4B ve toplam borcu ¥992.7B olup, bu da borç-öz sermaye oranını 59.2% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥3,735.5B ve ¥2,059.1B dir. Astellas Pharma 'in FAVÖK'ü ¥95.1B faiz karşılama oranı 53.8 dur. Şirketin ¥302.9B tutarında nakit ve kısa vadeli yatırımları bulunmaktadır.

Anahtar bilgiler

59.2%

Borç/özkaynak oranı

JP¥992.66b

Borç

Faiz karşılama oranı	53.8x
Nakit	JP¥302.93b
Eşitlik	JP¥1.68t
Toplam yükümlülükler	JP¥2.06t
Toplam varlıklar	JP¥3.74t

Son finansal sağlık güncellemeleri

Is Astellas Pharma (TSE:4503) A Risky Investment?

Jun 14

Recent updates

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Sep 24

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Sep 03

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Aug 20

Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

Aug 04

Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year

Jul 26

Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Apr 29

Why We're Not Concerned About Astellas Pharma Inc.'s (TSE:4503) Share Price

Feb 29

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4503 'nin kısa vadeli varlıkları ( ¥1,240.7B ) kısa vadeli yükümlülüklerini ( ¥1,373.8B ) kapsamıyor.

Uzun Vadeli Yükümlülükler: 4503 şirketinin kısa vadeli varlıkları ( ¥1,240.7B ) uzun vadeli yükümlülüklerini ( ¥685.3B ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4503 'nin net borç/öz sermaye oranı ( 41.1% ) yüksek olarak değerlendiriliyor.

Borcun Azaltılması: 4503 şirketinin borç/öz sermaye oranı son 5 yılda 0.1% seviyesinden 59.2% seviyesine yükseldi.

Borç Kapsamı: 4503 'nin borcu işletme nakit akışı ( 17.4% ) tarafından iyi bir şekilde karşılanmıyor.

Faiz Kapsamı: 4503 'in borcuna ilişkin faiz ödemeleri EBIT ( 53.8 x kapsam) tarafından iyi bir şekilde karşılanmaktadır.

Astellas Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 2/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Is Astellas Pharma (TSE:4503) A Risky Investment?

Recent updates

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Astellas Pharma Inc. Receives Approval from the European Commission for VYLOY in Combination with Chemotherapy for Advanced Gastric and Gastroesophageal Junction Cancer

Upcoming dividend of JP¥37.00 per share

Astellas Pharma Inc. to Present VEOZAH (fezolinetant) Data at 2024 Annual Meeting of The Menopause Society

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

European Commission Approves Astellas Pharma Inc.'s PADCEV in Combination with KEYTRUDA (Pembrolizumab) for First-Line Treatment of Advanced Urothelial Cancer

Astellas Pharma Inc. Initiates Phase 3 Clinical Study of Fezolinetant for VMS in Women with Breast Cancer Receiving Adjuvant Endocrine Therapy

Astellas Pharma (TSE:4503) Has Announced That It Will Be Increasing Its Dividend To ¥37.00

Astellas Pharma Inc. Announces Center for Drug Evaluation of China's National Medical Products Administration Approves Padcev (Enfortumab Vedotin) for Treatment of Locally Advanced or Metastatic Urothelial Cancer

Consensus EPS estimates increase by 11%

Consensus EPS estimates increase by 21%

Consensus EPS estimates fall by 15%

Earnings Beat: Astellas Pharma Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models

First quarter 2025 earnings: EPS and revenues exceed analyst expectations

Astellas Pharma Inc. Receives Positive Chmp Opinion for Zolbetuximab in Combination with Chemotherapy for Treatment of Advanced Gastric and Gastroesophageal Junction Cancer

Astellas Pharma's (TSE:4503) Shareholders Will Receive A Bigger Dividend Than Last Year

Astellas Pharma (TSE:4503) Is Paying Out A Larger Dividend Than Last Year

Consensus EPS estimates fall by 16%

Final dividend of JP¥37.00 announced

Astellas Pharma Inc. to Report Q1, 2025 Results on Aug 01, 2024

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Is Astellas Pharma (TSE:4503) A Risky Investment?

Consensus EPS estimates fall by 11%

U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date

U.S. Food and Drug Administration Acknowledges Astellas Pharma Inc.’ Resubmission of Biologics License Application for Zolbetuximab and Sets New Action Date

Consensus EPS estimates fall by 16%

Astellas Pharma's (TSE:4503) Soft Earnings Are Actually Better Than They Appear

Astellas Pharma Inc. Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Astellas Pharma Inc., Annual General Meeting, Jun 20, 2024

Astellas Pharma Inc. Announces European Commission Approval for Use in Additional Recurrent Early Prostate Cancer Treatment Setting

Astellas Pharma Inc. Revises Consolidated Earnings Guidance for the Year Ending March 31, 2024

Consensus EPS estimates fall by 14%

Astellas Pharma Inc. to Report Fiscal Year 2024 Results on Apr 25, 2024

U.S. FDA Accepts Astellas’ Supplemental New Drug Application for Izervay (Avacincaptad Pegol Intravitreal Solution) for Geographic Atrophy

China's National Medical Products Administration Accepts Astellas and Pfizer's Supplemental Biologics License Application for Enfortumab Vedotin with Keytruda (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc.'s Vyloy™? (zolbetuximab) Approves in Japan for Treatment of Gastric Cancer

Astellas Pharma Inc. Receives Positive CHMP Opinion for XTANDI™ in Additional Recurrent Early Prostate Cancer Treatment Setting

Upcoming dividend of JP¥35.00 per share

Astellas Pharma Initiates Phase 3 Clinical Studies of Fezolinetant for VMS Associated with Menopause in Japan

Why We're Not Concerned About Astellas Pharma Inc.'s (TSE:4503) Share Price

Astellas Pharma Inc. Announces Japan's Ministry of Health, Labour and Welfare Grants Priority Review for the Company's Supplemental New Drug Application (sNDA) for PADCEV with KEYTRUDA

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Astellas Pharma Inc. Submits Supplemental New Drug Application in Japan for PADCEV with KEYTRUDA for First-Line Treatment of Advanced Bladder Cancer

European Medicines Agency Validates Type II Variation Application for PADCEV®? (enfortumab Vedotin) with KEYTRUDA®? (Pembrolizumab) for First-Line Treatment of Advanced Bladder Cancer

Astellas Pharma Inc. Provides Update on Zolbetuximab Biologics License Application in U.S

Astellas Pharma Inc. to Report Q3, 2024 Results on Feb 05, 2024

Consensus EPS estimates fall by 11%

Astellas Pharma Inc. Announces EMA Recommends Arpraziquantel for Treatment of Schistosomiasis in Preschool-Aged Children

Astellas Pharma Inc. Announces That Its VEOZA™ (fezolinetant) Approved by European Commission for Treatment of Vasomotor Symptoms Associated with Menopause

Astellas Pharma US, Inc. Announces FDA Approves Expanded Use of CRESEMBA® (isavuconazonium sulfate) in Children with Invasive Aspergillosis and Invasive Mucormycosis

Astellas Pharma Inc. and Seagen Inc. Announces FDA Grants Priority Review for Supplemental Biologics License Application of Padcev with Keytruda for First-Line Treatment of Advanced Bladder Cancer

Astellas' Fezolinetant Reduces Frequency and Severity of VMS Associated with Menopause in Women Considered Unsuitable for Hormone Therapy

Pfizer and Astellas' Xtandi Approve by U.S. FDA in Earlier Prostate Cancer Treatment Setting

New minor risk - Profit margin trend

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Consensus EPS estimates fall by 11%

Seagen Inc. and Astellas Pharma Inc. Announces Results from the Phase 3 EV-302 Clinical Trial for PADCEV (Enfortumab Vedotin-Ejfv) in Combination with Keytruda (Pembrolizumab) Versus Chemotherapy

Astellas to Share New Data Across Hard-to-Treat Cancers During ESMO Congress 2023

Astellas Receives Positive Chmp Opinion for Veoza (Fezolinetant)

Astellas Pharma Inc. to Report Q2, 2024 Results on Nov 01, 2023

Astellas Pharma Inc. and Seagen Inc. Announces Positive Topline Results from the Phase 3 Ev-302 Clinical Trial

Upcoming dividend of JP¥35.00 per share at 3.3% yield

Astellas Pharma Inc. Announces China's National Medical Products Administration Accepts New Drug Application for Xtandi®? (Enzalutamide) in Metastatic Hormone-S Sensitive Prostate Cancer

Astellas Pharma Inc. Announces Positive 24-Month Topline Results from the Phase 3 GATHER2 Clinical Trial Evaluating the Efficacy and Safety of IZERVAY

European Medicines Agency Validates Type II Variation for Astellas' XTANDI (enzalutamide) for Treatment of Non-Metastatic Hormone-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

Sandoz AG completed the acquisition of Product Rights of MYCAMINE from Astellas Pharma Inc. (TSE:4503).

FDA Grants Priority Review for XTANDI in Non-Metastatic Castration-Sensitive Prostate Cancer with High-Risk Biochemical Recurrence

Astellas Pharma Inc. Announces European Medicines Agency Accepts for Regulatory Review the Marketing Authorization Application for Avacincaptad Pegol

U.S. FDA Accepts Astellas Pharma US, Inc.'s sNDA for CRESEMBA® (isavuconazonium sulfate) in Children

Astellas Pharma Inc. Announces the U.S. Food and Drug Administration Approves Izervay (Avacincaptad Pegol Intravitreal Solution) for the Treatment of Geographic At the 12-Month Primary Endpoint Across Two Phase 3 Clinical Trials

Astellas Pharma Inc. Revises Consolidated Earnings Guidance on Full Basis for the Full-Year 2023

First quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind